Page 9 - Solid Biosciences News Today

/PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), will host...

The U.S. Food and Drug Administration cleared a shortened version of a gene for a muscle protein to be used in 4- and 5-year-olds with muscular dystrophy.

If Sarepta's gene therapy SRP-9001 succeeded through this accelerated approval pathway, then many more can as well.

New York, June 15, 2023 (GLOBE NEWSWIRE) -- June 15, 2023 -- CureDuchenne, Muscular Dystrophy Association (MDA), and Parent Project Muscular Dystrophy...

Finepoint Capital LP acquired a new position in Solid Biosciences Inc. (NASDAQ:SLDB – Get Rating) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 218,562 shares of the company’s stock, valued at approximately $1,176,000. Solid Biosciences makes up approximately 0.4% of Finepoint Capital […]

Arcellx (NASDAQ:ACLX – Get Rating) and Solid Biosciences (NASDAQ:SLDB – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk and institutional ownership. Risk and Volatility Arcellx has a beta of -0.33, indicating […]

Solid Biosciences (NASDAQ:SLDB – Get Rating) and Arcellx (NASDAQ:ACLX – Get Rating) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability. Volatility and Risk Solid Biosciences has a beta of 1.47, indicating […]

Solid Biosciences (NASDAQ:SLDB – Get Rating) and Arcellx (NASDAQ:ACLX – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership. Risk & Volatility Solid Biosciences has a beta of 1.47, […]

DBV Technologies (NASDAQ:DBVT – Get Rating) and Solid Biosciences (NASDAQ:SLDB – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, analyst recommendations and profitability. Profitability This table compares DBV Technologies and Solid Biosciences’ […]

Current methods for assessing ambulatory function in patients with Duchenne muscular dystrophy do not fully reflect how they experience DMD in their...